Nanomedicine review: clinical developments in liposomal applications

Cancer Nanotechnology

Table 7 Efficacy of recent clinical trials with liposomal daunorubicin in mono or combined therapy

References	Years	Phase	Disease	LF	n	Dose	Efficacy
References	Years	Phase	Disease	LF	n	Dose	CR (%)	M-EFS (months)	OS rate (%)	M-OS (months)
Inman (2017)	2016	III	AML	CPX-351	153	100 units/m²/day	47.7	2.53	41.5^a	–
Cortes et al. (2015)	2015	II	AML	CPX-351	81	100 units/m²/day	49.4	4	36^c	8.5
Lancet et al. (2014)	2014	II	AML	CPX-351	85	100 units/m²/day	66.7	6.5	–	14.7
Gergis et al. (2013)	2013	I	AML	CPX-351	36	Dose escalation^a	72.2	3.2^b	37^c	8.3
Kaspers et al. (2013)	2013	III	AML	DaunoXome^® + fludarabine + cytarabine + filgrastim	197	60 mg/m²/day + 30 mg/m²/day + 2000 mg/m²/day + 200 μg/m²/dose	69	–	40^d	–
Creutzig et al. (2013)	2013	III	AML	Liposomal daunorubicin	257	60 mg/m²/day	89	59%^e	76^e	–

CR or complete remission, was defined as < 5% leukemic blasts in bone marrow with signs of normal hematopoiesis and of regeneration of normal peripheral blood cell production (platelets > 50 × 10⁹/L without transfusions, neutrophils > 1.0 × 10⁹/L) and no leukemic cells in the peripheral blood or anywhere else (Kaspers et al. 2013)
LF liposomal formulation, n number of patients, AML acute myeloid leukemia
^aIt is not described here
^bLeukemia-free survival
^cAt 1 year
^dAt 4 years
^eAt 5 years

ISSN: 1868-6966